Anastrozole 1 mg

Anastrozole is a synthetic small molecule belonging to the class of non-steroidal enzyme inhibitors, chemically a benzene derivative with a triazolylmethyl group and two tertiary nitrile groups. In scientific research, it is studied as a model compound for structure-activity relationships within the azole series and as a reference standard in analytical work. This compound is offered as 1 mg tablets, exclusively for laboratory and research purposes.

What is Anastrozole?

Anastrozole (2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile) is structured around a symmetrically 1,3,5-substituted benzene ring: two identical 2-cyanopropan-2-yl groups and a 1,2,4-triazole ring connected via a methylene bridge. Both nitrile functions are attached to fully substituted carbon atoms, making them sterically shielded and chemically unreactive. Furthermore, the methylene bridge grants the triazole ring more freedom of movement than in compounds where the azole is directly attached to a methine carbon, a structural difference that makes the molecule a valuable reference point in structure-activity research.

In research models, a ring nitrogen of the triazole binds to the heme iron in the active cavity of the enzyme aromatase (CYP19A1), thereby reversibly displacing the natural substrate. Because no covalent bond is formed, the inhibition is competitive in vitro and fully reversible. Small differences in the spatial orientation of the azole and in the nature of the side groups yield measurably different inhibition constants within the series, making the compound suitable for comparative kinetic work. Consequently, Anastrozole is used as a model compound and reference substance in scientific research.

Research areas

In a laboratory context, Anastrozole occurs in the following research areas, among others:

• Enzyme kinetic research into reversible inhibition of CYP19A1 in microsome and recombinant enzyme models.
• Structure-activity study within the triazole series, in which bridge length and substituent size are systematically varied.
• In vitro selectivity study of cross-reactivity with other cytochrome P450 isoforms.
• Research into steroid conversion and the androgen-estrogen balance in cell culture models.
• Analytical method development and validation (HPLC, LC-MS) using Anastrozole as a calibration substance for low-concentration determinations.
• Stability and solubility studies of nitrile-substituted azole compounds under controlled conditions.

Each of these applications involves controlled laboratory or preclinical model research.

Anastrozole in our research assortment

Anastrozole falls under the category of oral investigational compounds in solid tablet form within our range. Researchers working with this category regularly place the compound alongside other small molecules that are studied via their own biochemical target. While Anastrozole focuses on reversible, metal-coordinated enzyme inhibition, other components within the same product line have been specifically chosen to cover irreversible enzyme inactivation or receptor-linked targets. These compounds share the solid tablet form and the standardized amount of active substance per unit, but differ fundamentally in molecular class and the mechanism under investigation.

Specifications

Shape, handling and storage

Anastrozole is supplied as solid tablets with a standardized amount of 1 mg per tablet, packed in units of 100. With such a low concentration per unit, the majority of the tablet constitutes the excipient; therefore, in analytical work, multiple tablets are usually processed together and dissolved in a suitable analytical medium, after which the matrix components are separated by filtration or centrifugation.

Store the tablets dry at room temperature, protected from direct light and moisture, in the original packaging. The triazole ring and the shielded nitrile groups are chemically stable, but moisture absorption into the tablet matrix can affect the uniform distribution of the active substance. Handle the compound with the usual laboratory precautions: work in a clean environment, use suitable personal protective equipment, and prevent cross-contamination with other research materials. Keep the packaging out of reach of unauthorized persons.

Composition and lab results

For this compound, the content is expressed as the amount of active substance per tablet (1 mg per tablet) rather than as a purity percentage, as is customary for tablet and capsule formulations. Especially at a low content per unit, the uniformity of that distribution is the determining specification.

You can find an overview of the available analytical documentation on our lab results pageThe reports are collected centrally there, so that you can incorporate the data into your own research records.

Frequently Asked Questions

To which class of substances does Anastrozole belong?
Anastrozole is a synthetic small molecule from the non-steroidal triazole series and is classified as a reversible aromatase inhibitor of type II. It is not a peptide and therefore contains no amino acid sequence.

How does the structure differ from other triazole compounds?
The triazole is coupled to the benzene ring via a methylene bridge rather than directly to a methine carbon. As a result, the ring has greater freedom of movement when approaching the heme iron, and the two sterically shielded nitrile groups contribute in their own way to the fit within the active cavity. This makes the compound a suitable reference point in structure-activity studies.

In what form is the compound supplied?
As solid tablets with 1 mg active substance per tablet, packed in units of 100.

How do I store the tablets?
Dry, at room temperature and protected from light and moisture, preferably in the original packaging.